Rallybio reports Q3 2023 net loss of $18.4M ($0.45/share); cash $121.4M, runway into Q1 2025

Rallybio Corp

2023-Q3 EPS reported -$1.35

Net loss of $18.4M, or $0.45 per share, unchanged from Q3 2022 net loss of $18.4M ($0.60 per share).
R&D expenses $13.3M (up vs $12.1M in Q3 2022) on advancing RLYB212 and RLYB331; G&A expenses $6.1M (down from $6.8M).
Cash, cash equivalents and marketable securities $121.4M as of Sept 30, 2023; expected to fund operations into Q1 2025.
On track for 4Q 2023 data readouts: RLYB212 Phase 1 multiple dose cohort initial data and RLYB116 Phase 1 MAD data including safety, PK, PD.
RLYB212 Phase 2 dose confirmation study in pregnant women expected to initiate in H2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Rallybio Corp reported the third quarter ended September 30, 2023 results: net income Net loss was $18.4 million for the third quarter of 2023, or net loss per common share of $0.45, EPS net loss per common share of $0.45.

Period: the third quarter ended September 30, 2023
Net income: Net loss was $18.4 million for the third quarter of 2023, or net loss per common share of $0.45
EPS: net loss per common share of $0.45
Result: reported results

Exact text from the filing

Rallybio Corporation (Nasdaq: RLYB) today reported financial results for the third quarter ended September 30, 2023

View on SEC.gov

Browse all earnings releases →

Rallybio Corp filing history →

Source: SEC EDGAR

accession 0001739410-23-000011

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.